AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7951476
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of caffeine (in non-smoking controls)
Trial: 2889518
Drug: Amantadine 100
RxNorm normalized name: amantadine 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 100 mg bid
Trial: 30635862
Drug: Linkage to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linkage to care associated with treatment readiness
Trial: 30635862
Drug: Linkage to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linkage to care negatively associated with weekly alcohol consumption
Trial: 21865768
Drug: Pure sodium
RxNorm normalized name: Dream Pure BB
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pure sodium glycerophosphate formulation (reference)
Trial: 9764348
Drug: Heparin/Aspirin (H/A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin/Aspirin (H/A) alone
Trial: 9055693
Drug: Tetracycline solution
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline solution conditioning for 5 minutes
Trial: 9055693
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline solution rinse
Trial: 359904
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution 0.25% and 0.5%
Trial: 359904
Drug: Timolol alone
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol alone or in combination with a topical cholinergic agent or/and a systemic carbonic anhydrase inhibitor
Trial: 28917374
Drug: Bell pepper
RxNorm normalized name: Bell pepper
DrugBank: Green bell pepper (DB10556)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bell pepper juice (100 ml, twice/day) with integrated approach of yoga therapy (IAYT)
Trial: 18503578
Drug: Integrated approach
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated approach of yoga therapy (IAYT)
Trial: 21953572
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg single dose) in subjects receiving hemodialysis
Trial: 11738689
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray, administered once daily for 4 months.
Trial: 9283509
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d)
Trial: 29784554
Drug: Ibuprofen 600mg
RxNorm normalized name: IBUPROFEN 600MG TAB
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600mg pre-event
Trial: 27456464
Drug: Colla corii
RxNorm normalized name: CORID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colla corii asini (CCA) 15 g
Trial: 24981506
Drug: Adjuvant whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant whole brain radiotherapy (WBRT) following local treatment of intracranial melanoma metastases
Trial: 23053340
Drug: MicroPulse (MP)
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MicroPulse (MP) treatment at the active leakage site guided by fluorescein angiography (n=16 eyes)
Trial: 23053340
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.25 mg Bevacizumab (BCZ) (n=10 eyes)
Trial: 18344099
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of fomepizole (15 mg/kg)
Trial: 18344099
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of fomepizole (15 mg/kg)
Trial: 17148777
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTC group)
Trial: 17148777
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC group)
Trial: 17148777
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic chemotherapy (no-CT group)
Trial: 12663594
Drug: Thyroid function
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid function tests (TSH, thyroxine, triiodothyronine) annually and TPO antibodies every 4 years
Trial: 3901660
Drug: ORS60 (Na+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS60 (Na+ 60 mmol/l)
Trial: 29084918
Drug: Ontuxizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ontuxizumab (8 mg/kg) plus best supportive care
Trial: 27353315
Drug: 8-session cue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-session cue exposure therapy
Trial: 9646621
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg atorvastatin
Trial: 8848472
Drug: NSAIDs (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (aspirin and ibuprofen)
Trial: 28390209
Drug: Control: biotène®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: biotène® Gentle Mint Gel toothpaste (n = 77)
Trial: 20713865
Drug: Rasburicase (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasburicase (0.20 mg/kg/d intravenously days 1‐5)
Trial: 20713865
Drug: Rasburicase plus
RxNorm normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d days 1 to 3 followed by oral allopurinol 300 mg/d days 3 to 5)
Trial: 20713865
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg/d orally days 1 to 5)
Trial: 24965954
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health care using an oral moisture gel
Trial: 24965954
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral health care
Trial: 20504306
Drug: Intradermal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccine (15 microg HA/strain/0.1-ml dose)
Trial: 6313458
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg twice a day
Trial: 7038142
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (nephrectomy) and adjuvant active immunotherapy (bacillus Calmette‐Guerin)
Trial: 20810048
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2a (3 million units SC three times/week) + Ribavarin (1000 mg/day for weight ≤ 75kg; 1200 mg/day for weight > 75kg)
Trial: 20810048
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2b (3 million units SC three times/week) + Ribavarin (1000 mg/day for weight ≤ 75kg; 1200 mg/day for weight > 75kg)
Trial: 17469684
Drug: Clinical trials
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical trials of pharmacotherapy for dementia
Trial: 10414910
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF (group A)
Trial: 10414910
Drug: G-CSF administration
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF administration (both early and delayed)
Trial: 2221302
Drug: Continuous application
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous application of alfentanil (0.023 mg/kg b.w./h) and midazolam (0.10 mg/kg b.w./h)
Trial: 30920339
Drug: CDP-choline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline (500 mg) and galantamine (16 mg)
Trial: 25532954
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg capsaicin
Trial: 25532954
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg capsaicin
Trial: 25532954
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ASA
Trial: 25532954
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg capsaicin + 500 mg ASA
Trial: 25532954
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg capsaicin + 500 mg ASA
Trial: 9756018
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with mitomycin, mitoxanthrone and cisplatin (5 patients)
Trial: 9756018
Drug: Celiac axis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiac axis infusion regional chemotherapy with SpherexR microembolization (9 patients)
Trial: 8147340
Drug: Immune milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune milk (90 g daily for 10 weeks)
Trial: 22431578
Drug: Normokalemia (potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normokalemia (potassium 3.5-5.4 mmol/L)
Trial: 22431578
Drug: Hyperkalemia (potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperkalemia (potassium >5.4 mmol/L)
Trial: 11601016
Drug: Exogenous natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous natural porcine pulmonary surfactant (150 mg/kg)
Trial: 18048991
Drug: Miglitol administered
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol administered in two divided doses: 25 mg just before a meal and 25 mg at 15 min after the start of a meal
Trial: 16230541
Drug: Full-dose intraoperative
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose intraoperative radiotherapy with electrons (ELIOT)
Trial: 8020670
Drug: Methotrexate (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (15 mg/wk)
Trial: 29620392
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy (CBT)‐based guided self‐help (CBTgsh)
Trial: 15336814
Drug: L-arginine enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine enriched cardioplegia and non-cardioplegic reperfusion
Trial: 15336814
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-arginine)
Trial: 11433695
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (oral prednisolone 40 mg/d for 1 month)
Trial: 11433695
Drug: Various drug
RxNorm normalized name: VARIOUS DRUG CLASSES IN ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various drug treatments (including corticosteroids, colchicine, propylthiouracil, etc.)
Trial: 11433695
Drug: Monoclonal anti-TNFα
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal anti-TNFα antibodies
Trial: 8459988
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg orally 3 times daily)
Trial: 8459988
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg) and dexamethasone (8 mg) given orally
Trial: 31092548
Drug: Low systemic
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low systemic arterial compliance (SAC) defined as ≤0.64 mL/m²
Trial: 22490854
Drug: Fluorouracil plasma
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil plasma concentration <25 ng/ml
Trial: 22490854
Drug: Fluorouracil plasma
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil plasma concentration 25-35 ng/ml
Trial: 22490854
Drug: Fluorouracil plasma
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil plasma concentration >35 ng/ml
Trial: 19403952
Drug: 7.5% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% maltodextrin solution
Trial: 17166184
Drug: Physiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy and steroid injection therapy combined
Trial: 6405770
Drug: 9.2 mg
RxNorm normalized name: fusidate 49.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.2 mg of glyceryl trinitrate (GTN) cream (acute study)
Trial: 6405770
Drug: 9.2 mg
RxNorm normalized name: fusidate 49.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.2 mg of glyceryl trinitrate (GTN) cream (1 h post-application)
Trial: 6405770
Drug: 9.2 mg
RxNorm normalized name: fusidate 49.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.2 mg of glyceryl trinitrate (GTN) cream (chronic study)
Trial: 6405770
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of glyceryl trinitrate (GTN) cream (after 3 weeks)
Trial: 6405770
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (during the study)
Trial: 23412547
Drug: Humidification therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humidification therapy (HUM)
Trial: 8839294
Drug: Tridimensional Personality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tridimensional Personality Questionnaire administered to social phobia patients
Trial: 30945118
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 20 mg once daily (steady state) with lisinopril (20 mg single dose)
Trial: 30945118
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 20 mg once daily (steady state) with warfarin (25 mg single dose)
Trial: 30945118
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 20 mg once daily (steady state) with digoxin (500 μg single dose)
Trial: 30945118
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 20 mg once daily (steady state) with metformin (850 mg twice daily for 4 days)
Trial: 30945118
Drug: SNAC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNAC alone (300 mg single dose) with lisinopril, warfarin, digoxin, or metformin
Trial: 19092257
Drug: N-acetylcysteine (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1,200 mg/day)
Trial: 15921686
Drug: Metformin pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin pretreatment (1500 mg daily for 12 days, followed by clomiphene 150 mg daily for 5 days along with metformin)
Trial: 8573554
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) at a dose of 800 mg/day
Trial: 28973164
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT)
Trial: 29988707
Drug: Enhanced physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced physiotherapy care package (education, twice daily coached breathing exercises for a minimum of 2 days, and 30 minutes of daily supervised early rehabilitation for a minimum of five postoperative days)
Trial: 29988707
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care physiotherapy (education, single session of coached breathing exercises, and daily early ambulation for 15 minutes)
Trial: 26308708
Drug: Alfacalcidol at
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol at 1 μg/day
Trial: 26308708
Drug: Alendronate 35
RxNorm normalized name: ALENDRONATE 35MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 35 mg/week
Trial: 26308708
Drug: Commencement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commencement of glucocorticoid therapy
Trial: 7829908
Drug: Fleroxacin 300
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 300 mg once a day for 3 days (cholera), 7 days (Salmonella enteritis), 5 days (other infectious enteritis)
Trial: 29789908
Drug: Two-phasic contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-phasic contrast injection (25mgI/kg/s for 12 seconds in 1st phase and 3.0 ml/s for 7 seconds in 2nd phase) with two axial scans using smart-coverage technique.
Trial: 29789908
Drug: Conventional protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional protocol with contrast injection (25mgI/kg/s for 14 seconds) and helical/axial scanning.
Trial: 24176997
Drug: QVA149 110/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 110/50 μg
Trial: 25222881
Drug: Glycopyrronium 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium 50 μg
Trial: 22205617
Drug: roxatidine 75
RxNorm normalized name: roxatidine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 75 mg
Trial: 11901047
Drug: BG9719 alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG9719 alone (2 lower doses)
Trial: 4050842
Drug: sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sublingual nifedipine
Trial: 24177257
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of dual antiplatelet therapy (aspirin 100-200 mg daily and clopidogrel 75 mg daily)
Trial: 24177257
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of dual antiplatelet therapy (aspirin 100-200 mg daily and clopidogrel 75 mg daily)
Trial: 30463813
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin
Trial: 9787863
Drug: Remifentanil combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil combined with propofol (6 mg/kg/h)
Trial: 6440383
Drug: Breast-conserving therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-conserving therapy
Trial: 2502799
Drug: Intravenous m-chlorophenylpiperazine
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous m-chlorophenylpiperazine (0.1 mg/kg)
Trial: 2502799
Drug: Oral m-chlorophenylpiperazine
RxNorm normalized name: Cleeravue-M Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral m-chlorophenylpiperazine (0.5 mg/kg)
Trial: 782699
Drug: Methyl‐CCNU and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl‐CCNU and cyclophosphamide combination
Trial: 23283356
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 µg/kg)
Trial: 16713525
Drug: Complementary treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary treatments (acupuncture and hypnotherapy)
Trial: 12584861
Drug: Domestic bambuteral
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic bambuteral tablet
Trial: 12584861
Drug: Imported bambuteral
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported bambuteral tablet
Trial: 3281308
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: '00' Dexon subcutaneous and '00' prolene subcuticular sutures
Trial: 28399219
Drug: Multidisciplinary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidisciplinary intervention targeting identified risk factors including physiotherapy, occupational therapy, geriatric assessment, optometry, and medication management
Trial: 9059951
Drug: Nadolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (80 mg p.o. chronic therapy for 2 months)
Trial: 8368985
Drug: Benadryl (diphenhydramine),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benadryl (diphenhydramine), 50 mg
Trial: 3126122
Drug: Growth-hormone releasing
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth-hormone releasing hormone (GHRH)
Trial: 15301647
Drug: Panic Control
RxNorm normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panic Control Therapy (PCT)
Trial: 1315645
Drug: Arginine vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine vasopressin infusion (0.1 m‐units min‐1 kg‐1)
Trial: 29426574
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of orthosis, nerve/tendon gliding exercises, and ultrasound therapy